Eyenovia is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology, branded the Optejet®. MicroPine is Co.'s topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is Co.'s pharmacologic treatment for presbyopia, a non-preventable and age-related hardening of the lens that causes the gradual loss of the eye's ability to focus at near and impairs near visual acuity. MydCombi is Co.'s fixed combination formulation of phenylephrine-tropicamide for mydriasis. The EYEN stock yearly return is shown above.
The yearly return on the EYEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EYEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|